8-K: Larimar Therapeutics Announces FDA Lifts Partial Clinical Hold on Nomlabofusp Program, Shares Surge

The FDA has removed the partial clinical hold on Larimar Therapeutics' nomlabofusp program, allowing the company to proceed with dose escalation in its ongoing open-label extension study.

Summary

• Larimar Therapeutics announced that the FDA has removed the partial clinical hold on their nomlabofusp (CTI-1601) program for Friedreich's Ataxia (FA).
• The FDA's decision was based on a review of data from a Phase 2 dose exploration study, which included 25 mg and 50 mg cohorts.
• The company plans to escalate the dose to 50 mg in the ongoing open-label extension (OLE) study after further characterization of frataxin pharmacodynamics (PD) at the 25 mg dose.
• Interim data from the OLE study is expected in Q4 2024, and a Biologics License Application (BLA) submission is targeted for the second half of 2025.
• The Phase 2 study showed that nomlabofusp was generally well-tolerated, had a predictable pharmacokinetic profile, and demonstrated dose-dependent increases in frataxin levels in skin and buccal cells.
• In the 50 mg cohort, all patients with quantifiable levels at baseline and Day 14 achieved frataxin levels in skin cells over 33% of the average level observed in healthy volunteers, with 3 patients exceeding 50%.

Sentiment

Score: 9

Explanation: The document is highly positive due to the removal of the clinical hold, positive Phase 2 data, and a strong cash position. The company is progressing well towards its goals.

Positives

• The removal of the partial clinical hold by the FDA is a significant positive development for the nomlabofusp program.
• The Phase 2 study demonstrated that nomlabofusp is generally well-tolerated and has a predictable pharmacokinetic profile.
• The dose-dependent increase in frataxin levels in skin and buccal cells is a positive indicator of the drug's efficacy.
• The company has a strong cash position of approximately $239 million, providing a cash runway into 2026.
• The company has received Orphan Drug, Rare Pediatric Disease, Fast Track, and PRIME designations for nomlabofusp.

Negatives

• Further dose escalation above 50 mg will require submission of additional data for FDA review.
• One Phase 2 participant in the 25 mg cohort withdrew due to an allergic reaction, and one Phase 1 participant in the 50 mg cohort withdrew due to mild-to-moderate nausea and vomiting.

Risks

• The success of the nomlabofusp program is dependent on the results of ongoing and future clinical trials.
• The FDA may not ultimately agree with Larimar's nomlabofusp development strategy.
• The company's ability to raise additional capital is crucial for the continued development of its product candidates.
• There are risks associated with manufacturing and scaling the production of nomlabofusp.
• The company faces competition from other companies developing treatments for Friedreich's Ataxia.

Future Outlook

Larimar intends to pursue an accelerated approval pathway with the FDA and is planning to expand its clinical program to ex-U.S. geographies. The company is also planning to include pediatric patients in clinical development.

Management Comments

• We are very excited the FDA has removed the partial clinical hold on our nomlabofusp program following review of our Phase 2 data, said Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar.
• Helping patients with FA is our top priority and we appreciate the attention and thorough review by the FDA of all submitted data.
• Importantly, we are now cleared to dose escalate to the 50 mg dose in our ongoing OLE study which we plan to do following further characterization of frataxin PD at the 25 mg dose.

Industry Context

This announcement is significant for the Friedreich's Ataxia treatment landscape, as nomlabofusp is a potential first-in-class protein replacement therapy designed to address the underlying cause of the disease. The removal of the clinical hold positions Larimar as a key player in this space, competing with other companies developing treatments for FA.

Comparison to Industry Standards

• Larimar's nomlabofusp is a novel protein replacement therapy, differentiating it from other approaches like Reata Pharma/Biogen's Omaveloxolone (SKYCLARYS), which is an Nrf2 activator, and PTC Therapeutics' Vatiquinone, a 15-Lipoxygenase Inhibitor.
• While Omaveloxolone is already approved in the US and EU, it does not directly address the frataxin deficiency, which is the root cause of FA, as nomlabofusp aims to do.
• Lexeo Therapeutics' LX2006 is a gene therapy approach, which is a different mechanism of action compared to Larimar's protein replacement therapy.
• The Phase 2 data showing dose-dependent increases in frataxin levels in skin and buccal cells is a positive sign, as it indicates that nomlabofusp is having the desired effect on the target protein.
• The company's focus on achieving frataxin levels in patients that are a significant percentage of healthy volunteer levels is a key differentiator.

Stakeholder Impact

• Shareholders will likely react positively to the news of the clinical hold being lifted and the positive Phase 2 data.
• Patients with Friedreich's Ataxia and their families will be encouraged by the progress of the nomlabofusp program.
• Employees of Larimar will be motivated by the positive developments and the company's progress.
• The company's suppliers and partners will benefit from the continued development of the program.

Next Steps

• Larimar plans to dose escalate to 50 mg in the ongoing open-label extension study.
• The company will continue to enroll patients and activate additional sites for the open-label extension study.
• Interim data from the open-label extension study is expected in Q4 2024.
• Larimar intends to pursue an accelerated approval pathway with the FDA.
• The company is planning to expand its clinical program to ex-U.S. geographies.
• The company is planning to include pediatric patients in clinical development.

Key Dates

Keywords

nomlabofusp, Friedreich's Ataxia, FDA, clinical hold, frataxin, CTI-1601, protein replacement therapy, rare disease, clinical trial, biotechnology